MedTrace Logo

Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults

NCT06621810 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2024-10-01

No results posted yet for this study

Summary

The goal of this study is to develop supportive diagnostic artificial intelligence algorithms to distinguish melanoma from nevi or other benign pigmented skin lesions, especially in younger patients (below the age of 30). The main goals it aims to achieve are:

* development of an algorithm based on dermatoscopic images, targeting skin cancer screening in vulnerable populations
* development of another algorithm based on histological images, intended to be used by pathologists on lesions that are still suspicious of melanoma after dermatologic assessment
* implementation of explainability methods to enable the user to better comprehend the systems' decisions, avoid biases and increase trust in these applications

There is no additional time commitment for the study participants for this study, as the data used in this project will be collected in routine clinical practice anyway.

Conditions

  • Melanoma (Skin Cancer)
  • Artificial Intelligence (AI)
  • Pediatric Cancer

Sponsors & Collaborators

  • Universität Tübingen

    collaborator OTHER

  • University of Florence

    collaborator OTHER

  • Fundacio Clinic Barcelona

    collaborator OTHER

  • Hospital Clinic of Barcelona

    collaborator OTHER

  • German Cancer Research Center

    lead OTHER

Principal Investigators

  • Titus J Brinker, PD Dr. med · German Cancer Research Center

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06621810 on ClinicalTrials.gov